Benzinga · Sep 10, 2026
Citigroup Maintains Buy on Stryker, Lowers Price Target to $360
Citigroup analyst Joanne Wuensch maintains Stryker (NYSE:SYK) with a Buy and lowers the price target from $399 to $360.
NASDAQ · SYK
Stryker Corporation
Healthcare · Medical - Devices
$281.50
Down-$0.37 (-0.13%)
Updated Sep 16, 2026, 12:12 PM
SID Score
4.7/10
Composite research score
Smart Money
46/100
Neutral
- Market cap
- 134.97B
- P/E ratio
- 45.86
- Dividend yield
- 1.19%
- 52-week range
- $267.00 – $389.33
- Volume
- 3.46M
- Avg. volume
- 1.61M
Price performance
SYK price history
1M range · 20 trading sessions · Daily adjusted prices
SYK closed at $281.50 after 20 trading sessions, down 15.05% for the selected period.
- Last close
- $281.50
- Period change
- -15.05%
- Period low
- $270.01
- Period high
- $339.98
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $281.00 | $282.69 | $277.62 | $281.50 | 3.46M |
| Sep 14, 2026 | $282.31 | $287.165 | $280.67 | $281.87 | 2.94M |
| Sep 11, 2026 | $270.72 | $277.00 | $267.00 | $275.56 | 3.72M |
| Sep 10, 2026 | $274.62 | $278.00 | $269.64 | $270.01 | 3.48M |
| Sep 9, 2026 | $271.835 | $278.745 | $270.85 | $275.39 | 5.5M |
| Sep 8, 2026 | $301.00 | $301.505 | $275.10 | $276.43 | 6.32M |
| Sep 4, 2026 | $304.49 | $307.545 | $302.51 | $303.13 | 2.4M |
| Sep 3, 2026 | $313.96 | $319.50 | $306.50 | $307.99 | 2.66M |
| Sep 2, 2026 | $315.06 | $321.745 | $311.38 | $312.19 | 2.19M |
| Sep 1, 2026 | $329.83 | $331.50 | $316.85 | $317.40 | 2.14M |
| Aug 31, 2026 | $327.79 | $329.50 | $323.12 | $323.80 | 2.04M |
| Aug 28, 2026 | $322.61 | $332.72 | $322.12 | $330.69 | 2.23M |
| Aug 27, 2026 | $326.845 | $328.4499 | $321.60 | $322.12 | 2.17M |
| Aug 26, 2026 | $329.13 | $333.39 | $326.41 | $329.67 | 1.57M |
| Aug 25, 2026 | $325.09 | $331.75 | $324.00 | $330.59 | 2.2M |
| Aug 24, 2026 | $330.00 | $334.87 | $327.01 | $327.81 | 1.88M |
| Aug 21, 2026 | $326.03 | $332.55 | $324.00 | $329.45 | 3.16M |
| Aug 20, 2026 | $338.26 | $342.35 | $327.47 | $327.70 | 2.23M |
| Aug 19, 2026 | $331.74 | $343.90 | $331.00 | $339.98 | 2.19M |
| Aug 18, 2026 | $336.995 | $339.24 | $331.04 | $331.37 | 3.18M |
Latest SYK news
The latest Smart Investors Daily articles mentioning SYK.
Stock researchCompany · Overview
SYK research
Overview
Company profile and research snapshot.
Company profile
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $419.33
- Implied upside
- —
- Analysts
- 18
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | Citigroup | Buy | — |
| Sep 9, 2026 | Wells Fargo | Overweight | — |
| Aug 13, 2026 | Wolfe Research | Peer Perform | — |
| Aug 3, 2026 | Citizens | Market Outperform | — |
| Jul 31, 2026 | Truist Securities | Hold | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 10, 2026
Stryker stock falls on slower peripheral vascular, hip sales
CFO Preston Wells said at a healthcare conference that the company is still working through supply issues in its peripheral vascular business and had fewer hip sales than expected so far this quarter.
Yahoo · Sep 9, 2026
Pulmera Appoints Jared Slibeck Chief Commercial Officer
Twenty-year industry veteran in surgical navigation and enabling technology joins Pulmera to spearhead commercial adoption of its CBeam™ 3D Imaging Platform, the first C-Arm Native 3D imaging system. 20-Year Stryker Veteran Jared Slibeck Joins Pulmera as Chief Commercial Officer Jared Slibeck has been named Chief Commercial Officer for Pulmera, effective September 1, 2026. Slibeck will lead the company’s commercial strategy and market development as the company brings the CBeam™ 3D Imaging Platf
Benzinga · Sep 9, 2026
Wells Fargo Maintains Overweight on Stryker, Lowers Price Target to $348
Wells Fargo analyst Larry Biegelsen maintains Stryker (NYSE:SYK) with a Overweight and lowers the price target from $418 to $348.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
